These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 34075346)

  • 1. Simeprevir Potently Suppresses SARS-CoV-2 Replication and Synergizes with Remdesivir.
    Lo HS; Hui KPY; Lai HM; He X; Khan KS; Kaur S; Huang J; Li Z; Chan AKN; Cheung HH; Ng KC; Ho JCW; Chen YW; Ma B; Cheung PM; Shin D; Wang K; Lee MH; Selisko B; Eydoux C; Guillemot JC; Canard B; Wu KP; Liang PH; Dikic I; Zuo Z; Chan FKL; Hui DSC; Mok VCT; Wong KB; Mok CKP; Ko H; Aik WS; Chan MCW; Ng WL
    ACS Cent Sci; 2021 May; 7(5):792-802. PubMed ID: 34075346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C virus drugs that inhibit SARS-CoV-2 papain-like protease synergize with remdesivir to suppress viral replication in cell culture.
    Bafna K; White K; Harish B; Rosales R; Ramelot TA; Acton TB; Moreno E; Kehrer T; Miorin L; Royer CA; García-Sastre A; Krug RM; Montelione GT
    Cell Rep; 2021 May; 35(7):109133. PubMed ID: 33984267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CL
    Ma L; Li Q; Xie Y; Jianyuan Zhao ; Yi D; Guo S; Guo F; Wang J; Yang L; Cen S
    Antiviral Res; 2022 Nov; 207():105419. PubMed ID: 36155070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication
    Shytaj IL; Fares M; Gallucci L; Lucic B; Tolba MM; Zimmermann L; Adler JM; Xing N; Bushe J; Gruber AD; Ambiel I; Taha Ayoub A; Cortese M; Neufeldt CJ; Stolp B; Sobhy MH; Fathy M; Zhao M; Laketa V; Diaz RS; Sutton RE; Chlanda P; Boulant S; Bartenschlager R; Stanifer ML; Fackler OT; Trimpert J; Savarino A; Lusic M
    mBio; 2022 Apr; 13(2):e0370521. PubMed ID: 35229634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of simeprevir on the replication of SARS-CoV-2 in vitro and in transgenic hACE2 mice.
    Muturi E; Hong W; Li J; Yang W; He J; Wei H; Yang H
    Int J Antimicrob Agents; 2022 Jan; 59(1):106499. PubMed ID: 34929295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repurposing simeprevir, calpain inhibitor IV and a cathepsin F inhibitor against SARS-CoV-2 and insights into their interactions with M
    J A; Francis D; C S S; K G A; C S; Variyar EJ
    J Biomol Struct Dyn; 2022 Jan; 40(1):325-336. PubMed ID: 32873185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.
    Gordon CJ; Tchesnokov EP; Woolner E; Perry JK; Feng JY; Porter DP; Götte M
    J Biol Chem; 2020 May; 295(20):6785-6797. PubMed ID: 32284326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remdesivir Strongly Binds to Both RNA-Dependent RNA Polymerase and Main Protease of SARS-CoV-2: Evidence from Molecular Simulations.
    Nguyen HL; Thai NQ; Truong DT; Li MS
    J Phys Chem B; 2020 Dec; 124(50):11337-11348. PubMed ID: 33264025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice.
    Pruijssers AJ; George AS; Schäfer A; Leist SR; Gralinksi LE; Dinnon KH; Yount BL; Agostini ML; Stevens LJ; Chappell JD; Lu X; Hughes TM; Gully K; Martinez DR; Brown AJ; Graham RL; Perry JK; Du Pont V; Pitts J; Ma B; Babusis D; Murakami E; Feng JY; Bilello JP; Porter DP; Cihlar T; Baric RS; Denison MR; Sheahan TP
    Cell Rep; 2020 Jul; 32(3):107940. PubMed ID: 32668216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2
    Gammeltoft KA; Zhou Y; Duarte Hernandez CR; Galli A; Offersgaard A; Costa R; Pham LV; Fahnøe U; Feng S; Scheel TKH; Ramirez S; Bukh J; Gottwein JM
    Antimicrob Agents Chemother; 2021 Aug; 65(9):e0268020. PubMed ID: 34097489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus.
    Gordon CJ; Tchesnokov EP; Feng JY; Porter DP; Götte M
    J Biol Chem; 2020 Apr; 295(15):4773-4779. PubMed ID: 32094225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Investigational Anti-SARS-CoV-2 Agent Ensitrelvir "S-217622": A Very Promising Potential Universal Broad-Spectrum Antiviral at the Therapeutic Frontline of Coronavirus Species.
    Eltayb WA; Abdalla M; Rabie AM
    ACS Omega; 2023 Feb; 8(6):5234-5246. PubMed ID: 36798145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Strategies of Antiviral Drug Discovery for COVID-19.
    Mei M; Tan X
    Front Mol Biosci; 2021; 8():671263. PubMed ID: 34055887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of Remdesivir in Comparison with Five Approved Antiviral Drugs for Inhibition of RdRp in Combat with SARS-CoV-2.
    Mahdian S; Arab SS
    Iran J Sci Technol Trans A Sci; 2022; 46(5):1359-1367. PubMed ID: 36187298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
    Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
    Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
    Uzunova K; Filipova E; Pavlova V; Vekov T
    Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corilagin inhibits SARS-CoV-2 replication by targeting viral RNA-dependent RNA polymerase.
    Li Q; Yi D; Lei X; Zhao J; Zhang Y; Cui X; Xiao X; Jiao T; Dong X; Zhao X; Zeng H; Liang C; Ren L; Guo F; Li X; Wang J; Cen S
    Acta Pharm Sin B; 2021 Jun; 11(6):1555-1567. PubMed ID: 33614402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viral target and metabolism-based rationale for combined use of recently authorized small molecule COVID-19 medicines: Molnupiravir, nirmatrelvir, and remdesivir.
    Yan D; Yan B
    Fundam Clin Pharmacol; 2023 Aug; 37(4):726-738. PubMed ID: 36931725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2-((1H-indol-3-yl)thio)-N-phenyl-acetamides: SARS-CoV-2 RNA-dependent RNA polymerase inhibitors.
    Zhao J; Zhang G; Zhang Y; Yi D; Li Q; Ma L; Guo S; Li X; Guo F; Lin R; Luu G; Liu Z; Wang Y; Cen S
    Antiviral Res; 2021 Dec; 196():105209. PubMed ID: 34801588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic potential of green tea catechin, (-)-epigallocatechin-3-
    Dinda B; Dinda S; Dinda M
    Phytomed Plus; 2023 Feb; 3(1):100402. PubMed ID: 36597465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.